Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphoinositide 3-kinase (PI3K) pathway is frequently dysregulated in cancer.
• The p110α catalytic subunit of PI3K is a key driver of this dysregulation due to oncogenic mutations.
• Understanding PI3K p110α activation mechanisms is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To review recent advancements in the structural and functional understanding of the PI3K p110α enzyme.
• To explore the mechanisms of common oncogenic mutations affecting p110α.
• To summarize the progress in developing isoform-selective PI3K inhibitors and their pharmacological applications.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of structural and functional data for PI3K p110α.
• Examination of preclinical and clinical data on PI3K p110α inhibitors.

Main Results:

• Detailed insights into the structure and function of PI3K p110α.
• Elucidation of how specific oncogenic mutations activate p110α.
• Overview of emerging p110α-selective inhibitors and their therapeutic potential.

Conclusions:

• Targeting PI3K p110α represents a promising strategy for cancer treatment.
• Continued research into PI3K p110α structure, function, and inhibition is vital.
• Development of selective inhibitors holds potential for improved cancer therapy with reduced side effects.